SPOTLIGHT -
Background of the Prophage G-200 Vaccine for Recurrent Glioblastoma Multiforme
Andrew T. Parsa MD, PhD, from the University of California, San Francisco, discusses the background of the prophage G-200 vaccine for recurrent glioblastoma multiforme.
Administering the G-200 Vaccine
Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.
The Development of Prophage G-200 Vaccine for Recurrent Glioblastoma Multiforme
Andrew T. Parsa MD, PhD, describes the development and trial involving prophage G-200, a vaccine for recurrent glioblastoma multiforme.
